About Beta Bionics
Beta Bionics is a company based in Boston (United States) founded in 2015 by Firas Khatib. Beta Bionics has raised $348.92 million across 10 funding rounds from investors including Dexcom, Novo Nordisk and Marshall Wace. The company has 291 employees as of December 31, 2024. Beta Bionics offers products and services including iLet Bionic Pancreas, iLet App, and Bionic Circle. Beta Bionics operates in a competitive market with competitors including Sernova, Inreda Diabetic, Defymed, XOStem and Captix, among others.
- Headquarter Boston, United States
- Employees 291 as on 31 Dec, 2024
- Founders Firas Khatib
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Beta Bionics, Inc.
-
Annual Revenue
$65.12 M (USD)442.93as on Dec 31, 2024
-
Net Profit
-$54.76 M (USD)-24.17as on Dec 31, 2024
-
EBITDA
-$42.97 M (USD)-27.28as on Dec 31, 2024
-
Total Equity Funding
$348.92 M (USD)
in 10 rounds
-
Latest Funding Round
$60 M (USD), Series E
Nov 13, 2024
-
Investors
Dexcom
& 16 more
-
Employee Count
291
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Beta Bionics
Beta Bionics is a publicly listed company on the NASDAQ with ticker symbol BBNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Beta Bionics
Beta Bionics offers a comprehensive portfolio of products and services, including iLet Bionic Pancreas, iLet App, and Bionic Circle.
Automated device for insulin dosing based on glucose data.
Mobile application for managing bionic pancreas features.
Network for sharing diabetes management with family members.
People of Beta Bionics
Unlock access to complete
Funding Insights of Beta Bionics
Beta Bionics has successfully raised a total of $348.92M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $60 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Beta Bionics
Beta Bionics has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Dexcom, Novo Nordisk and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Eventide is engaged in values-based investment management services.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Beta Bionics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beta Bionics
Investment portfolio details for Beta Bionics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Beta Bionics
Detailed financials for Beta Bionics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Beta Bionics Comparisons
Peer comparison for Beta Bionics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Beta Bionics
Beta Bionics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sernova, Inreda Diabetic, Defymed, XOStem and Captix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative medicine to deliver proteins and hormones for disease treatment
|
|
| Locked | Locked | Locked |
Bi-hormonal artificial pancreas is developed for autonomous glucose regulation.
|
|
| Locked | Locked | Locked |
Develops innovative bio-artificial pancreas technologies for type 1 diabetes treatment.
|
|
| Locked | Locked | Locked |
Stem cells and bio-artificial organs are developed for diabetes treatment.
|
|
| Locked | Locked | Locked |
Develops innovative bioartificial pancreas technologies for diabetes treatment.
|
Detailed competitors of Beta Bionics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beta Bionics
Complete news archive for Beta Bionics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beta Bionics
Beta Bionics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Beta Bionics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Beta Bionics is a funded company, having raised a total of $348.92M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Beta Bionics is 291.
Annual revenue of Beta Bionics is $65.12M as on Dec 31, 2024.
Beta Bionics was founded in 2015 and is headquartered in Boston, United States. The company operates in the medical device sector, focusing on diabetes management technologies. A bionic pancreas system called iLet is being developed to deliver autonomous glycemic control for individuals with type 1 diabetes. Operations center on research, development, and clinical validation of this system to support insulin delivery and glucose monitoring.
Beta Bionics's top competitors include Sernova, Inreda Diabetic and XOStem.
Beta Bionics offers iLet Bionic Pancreas, iLet App, and Bionic Circle.
Yes, Beta Bionics is publicly traded on NASDAQ under the ticker symbol BBNX.
Beta Bionics has 17 investors. Key investors include Dexcom, Novo Nordisk, Marshall Wace, HHS, and Zealand Pharma.
The ticker symbol of Beta Bionics is BBNX on NASDAQ.